# US 2021/0330763 A1 · Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs, and tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330763 A1
- Document ID: US20210330763A1
- Status: Published application
- Kind: A1
- Application number: 17/305,649
- Filed: 2021-07-12
- Published: 2021-10-28
- Earliest claimed: 2015-06-23
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Katherine A. HIGH; Xavier ANGUELA
- Web page: https://patentgrep.com/patent/US20210330763A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 15/86: Viral vectors
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.

## Claims

### Claim 1

A method of treating a human subject with severe or moderate hemophilia B comprising:
administering to said subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) vector comprising a vector genome encapsidated by an AAV capsid,
wherein said vector genome comprises at least two AAV inverted terminal repeats (ITR), an expression control element conferring liver tissue-specific expression operably linked with a nucleic acid sequence encoding human Factor IX (FIX) protein, and a polyadenylation signal sequence, wherein said nucleic acid sequence encoding human FIX protein is at least 70% identical to SEQ ID NO:10, has a reduced number of CpG di-nucleotides compared to wild-type nucleic acid sequence encoding human FIX protein and encodes the same human FIX protein encoded by SEQ ID NO:10,
wherein said therapeutically effective amount of said rAAV vector is a dose of at least 5×1011 vector genomes per kilogram (vg/kg) subject body weight, and is effective to reduce the severe or moderate hemophilia B to mild hemophilia B or a hemophilia B disease-free state.

### Claim 2 (depends on 1)

The method of claim 1, wherein said nucleic acid sequence encoding human FIX protein is at least 80% identical to SEQ ID NO:10.

### Claim 3 (depends on 2)

The method of claim 2, wherein said nucleic acid sequence encoding human FIX protein is at least 85% identical to SEQ ID NO:10.

### Claim 4 (depends on 1)

The method of claim 1, wherein said vector genome further comprises an intron.

### Claim 5 (depends on 4)

The method of claim 4, wherein said intron is positioned within said nucleic acid sequence encoding human FIX protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein said vector genome is linear single-stranded DNA.

### Claim 7 (depends on 1)

The method of claim 1, wherein an AAV ITR is positioned at each end of the vector genome, and said expression control element comprises an enhancer and a promoter.

### Claim 8 (depends on 7)

The method of claim 7, wherein said AAV ITRs are AAV2 ITRs, said enhancer is a human apolipoprotein HCR enhancer, and said promoter is a human alpha-1-antitrypsin gene promoter.

### Claim 9 (depends on 7)

The method of claim 7, wherein said AAV capsid is selected from the group consisting of:
(i) an AAV capsid of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, or AAV-2i8;
(ii) an AAV capsid comprising a VP1 protein consisting of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9;
(iii) an AAV capsid comprising a VP1 protein consisting of the amino acid sequence of SEQ ID NO:1 with an amino acid substitution at any one or more of amino acid positions 195, 199, 201 or 202 in SEQ ID NO:1; and
(iv) an AAV capsid comprising a VP1 protein consisting of the amino acid sequence of SEQ ID NO:1 with an amino acid substitution of arginine for any one or more lysines in SEQ ID NO:1.

### Claim 10 (depends on 7)

The method of claim 7, wherein said therapeutically effective amount of said rAAV vector is a dose ranging from 1×1012 to 5×1013 vg/kg subject body weight, and wherein said AAV capsid is an AAV5 capsid.

### Claim 11 (depends on 10)

The method of claim 10, wherein said therapeutically effective amount of said rAAV vector is a dose selected from the group consisting of 1×1012, 2×1012, 3×1012, 4×1012, 5×1012, 6×1012, 7×1012, 8×1012, 9×1012, 1×1013, 2×1013, 3×1013, 4×1013, and 5×1013 vg/kg subject body weight.

### Claim 12 (depends on 11)

The method of claim 11, wherein said therapeutically effective amount of said rAAV vector is a dose of 2×1013 vg/kg subject body weight.

### Claim 13 (depends on 10)

The method of claim 10, wherein said AAV ITRs are AAV2 ITRs, said enhancer is a human apolipoprotein HCR enhancer, and said promoter is a human alpha-1-antitrypsin gene promoter.

### Claim 14 (depends on 13)

The method of claim 13, wherein said therapeutically effective amount of said rAAV vector is a dose of 2×1013 vg/kg subject body weight.

### Claim 15 (depends on 13)

The method of claim 13, wherein said vector genome further comprises an intron positioned between said promoter and said nucleic acid sequence encoding human FIX protein.

### Claim 16 (depends on 15)

The method of claim 15, wherein said therapeutically effective amount of said rAAV vector is a dose of 2×1013 vg/kg subject body weight.

### Claim 17 (depends on 1)

The method of claim 1, wherein said treatment is effective to produce an average FIX activity of at least 20% of normal for a sustained period of at least 6 months.

### Claim 18 (depends on 1)

The method of claim 1, wherein said treatment is effective to produce an average FIX activity of at least 30% of normal for a sustained period of at least 12 months.

### Claim 19 (depends on 1)

The method of claim 1, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 0.50 IU/mL.

### Claim 20 (depends on 1)

The method of claim 1, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 1.50 IU/mL.

### Claim 21 (depends on 10)

The method of claim 10, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 0.50 IU/mL.

### Claim 22 (depends on 10)

The method of claim 10, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 1.50 IU/mL.

### Claim 23 (depends on 12)

The method of claim 12, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 0.50 IU/mL.

### Claim 24 (depends on 12)

The method of claim 12, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 1.50 IU/mL.

### Claim 25 (depends on 14)

The method of claim 14, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 0.50 IU/mL.

### Claim 26 (depends on 14)

The method of claim 14, wherein said treatment is effective to produce plasma FIX levels of about 0.06 to 1.50 IU/mL.

### Claim 27 (depends on 1)

The method of claim 1, wherein said treatment is effective to reduce the average frequency of FIX replacement therapy needed to control bleeding by at least 80%.

### Claim 28 (depends on 1)

The method of claim 1, wherein said treatment is effective to reduce the average frequency of spontaneous bleeding episodes by at least 80%.

### Claim 29 (depends on 1)

The method of claim 1, wherein said treatment is effective to produce average FIX activity of 30% to 50% of normal 12 months after administration with a standard deviation of 15% or less.

### Claim 30 (depends on 1)

The method of claim 1, wherein said treatment does not cause circulating liver enzyme levels to exceed 100% of the upper limit of normal value.
